Literature DB >> 31516110

TcTASV Antigens of Trypanosoma cruzi: Utility for Diagnosis and High Accuracy as Biomarkers of Treatment Efficacy in Pediatric Patients.

Noelia Floridia-Yapur1,2, Mercedes Monje-Rumi3, Paula Ragone3, Juan J Lauthier3, Nicolás Tomasini3, Anahí Alberti D'Amato3, Patricio Diosque3, Rubén Cimino1,2, José F Gil2,4, Daniel O Sanchez5, Julio R Nasser1, Valeria Tekiel5.   

Abstract

The discovery and characterization of novel parasite antigens to improve the diagnosis of Trypanosoma cruzi by serological methods and for accurate and rapid follow-up of treatment efficiency are still needed. TcTASV is a T. cruzi-specific multigene family, whose products are expressed on the parasite stages present in the vertebrate host. In a previous work, a mix of antigens from subfamilies TcTASV-A and TcTASV-C (Mix A + C) was sensitive and specific to identify dogs with active infection of high epidemiological relevance. Here, TcTASV-A and TcTASV-C were assayed separately as well as together (Mix A + C) in an ELISA format on human samples. The Mix A + C presented moderate sensitivity (78%) but high diagnostic accuracy with a 100% of specificity, evaluated on healthy, leishmaniasic, and Strongyloides stercoralis infected patients. Moreover, antibody levels of pediatric patients showed-2 years posttreatment-diminished reactivity against the Mix A + C (P < 0.0001), pointing TcTASV antigens as promising tools for treatment follow-up.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31516110      PMCID: PMC6838575          DOI: 10.4269/ajtmh.18-0936

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  20 in total

1.  Benznidazole treatment in chronic children infected with Trypanosoma cruzi: serological and molecular follow-up of patients and identification of Discrete Typing Units.

Authors:  M M Monje Rumi; C Pérez Brandán; J F Gil; A M Alberti D'Amato; P G Ragone; J J Lauthier; N Tomasini; R O Cimino; V Orellana; C D Lacunza; J R Nasser; M A Basombrío; P Diosque
Journal:  Acta Trop       Date:  2013-07-20       Impact factor: 3.112

2.  Treatment and seroconversion in a cohort of children suffering from recent chronic Chagas infection in Yoro, Honduras.

Authors:  Josep M Escribà; Elisa Ponce; Alberto de Dios Romero; Pedro Albajar Viñas; Andrea Marchiol; Glòria Bassets; Pedro Pablo Palma; M Angeles Lima; Concepción Zúniga; Carlos Ponce
Journal:  Mem Inst Oswaldo Cruz       Date:  2009-11       Impact factor: 2.743

3.  Research priorities for Chagas disease, human African trypanosomiasis and leishmaniasis.

Authors: 
Journal:  World Health Organ Tech Rep Ser       Date:  2012

4.  The Trypomastigote Small Surface Antigen from Trypanosoma cruzi Improves Treatment Evaluation and Diagnosis in Pediatric Chagas Disease.

Authors:  Virginia Balouz; Luciano J Melli; Romina Volcovich; Guillermo Moscatelli; Samanta Moroni; Nicolás González; Griselda Ballering; Margarita Bisio; Andrés E Ciocchini; Carlos A Buscaglia; Jaime Altcheh
Journal:  J Clin Microbiol       Date:  2017-10-04       Impact factor: 5.948

5.  Identification of novel vaccine candidates for Chagas' disease by immunization with sequential fractions of a trypomastigote cDNA expression library.

Authors:  Valeria Tekiel; Catalina D Alba-Soto; Stella M González Cappa; Miriam Postan; Daniel O Sánchez
Journal:  Vaccine       Date:  2009-01-20       Impact factor: 3.641

6.  TcTASV: a novel protein family in trypanosoma cruzi identified from a subtractive trypomastigote cDNA library.

Authors:  Elizabeth A García; María Ziliani; Fernán Agüero; Guillermo Bernabó; Daniel O Sánchez; Valeria Tekiel
Journal:  PLoS Negl Trop Dis       Date:  2010-10-05

7.  Impact of aetiological treatment on conventional and multiplex serology in chronic Chagas disease.

Authors:  Rodolfo Viotti; Carlos Vigliano; María Gabriela Alvarez; Bruno Lococo; Marcos Petti; Graciela Bertocchi; Alejandro Armenti; Ana María De Rissio; Gretchen Cooley; Rick Tarleton; Susana Laucella
Journal:  PLoS Negl Trop Dis       Date:  2011-09-06

Review 8.  Course of Chronic Trypanosoma cruzi Infection after Treatment Based on Parasitological and Serological Tests: A Systematic Review of Follow-Up Studies.

Authors:  Yanina Sguassero; Cristina B Cuesta; Karen N Roberts; Elizabeth Hicks; Daniel Comandé; Agustín Ciapponi; Sergio Sosa-Estani
Journal:  PLoS One       Date:  2015-10-05       Impact factor: 3.240

9.  Development of a Novel Multiplex Immunoassay Multi-cruzi for the Serological Confirmation of Chagas Disease.

Authors:  Elodie Granjon; Marie-Laure Dichtel-Danjoy; Esber Saba; Ester Sabino; Lea Campos de Oliveira; Maan Zrein
Journal:  PLoS Negl Trop Dis       Date:  2016-04-01

10.  The protein family TcTASV-C is a novel Trypanosoma cruzi virulence factor secreted in extracellular vesicles by trypomastigotes and highly expressed in bloodstream forms.

Authors:  Lucas D Caeiro; Catalina D Alba-Soto; Mariana Rizzi; María Elisa Solana; Giselle Rodriguez; Agustina M Chidichimo; Matías E Rodriguez; Daniel O Sánchez; Gabriela V Levy; Valeria Tekiel
Journal:  PLoS Negl Trop Dis       Date:  2018-05-04
View more
  1 in total

Review 1.  Vaccine Design against Chagas Disease Focused on the Use of Nucleic Acids.

Authors:  Edio Maldonado; Sebastian Morales-Pison; Fabiola Urbina; Aldo Solari
Journal:  Vaccines (Basel)       Date:  2022-04-12
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.